November 13, 2025
Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
November 3, 2025
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
October 29, 2025
Immutep Quarterly Activities Report Q1 FY26
October 20, 2025
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Two Posters at ESMO Congress 2025 Highlight Immutep’s Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer
October 13, 2025
Immutep Announces Successful Completion of FDA Project Optimus Requirements
CTOS 2025 Annual Meeting – EFTISARC-NEO trial with neoadjuvant eftilagimod alfa (Soft Tissue Sarcoma)
Immutep Corporate Presentation
October 19, 2025
ESMO Congress 2025 – EFTISARC-NEO (Soft Tissue Sarcoma)
October 18, 2025
ESMO Congress 2025 – INSIGHT-003 (First Line Non-Small Cell Lung Cancer)
ESMO Congress 2025 – TACTI-004 (First Line Non-Small Cell Lung Cancer)
December 12, 2024
ESMO Immuno-Oncology 2024 – TACTI-003, Cohort B (Metastatic Head and Neck Squamous Cell Carcinoma)
November 27, 2025 – November 27, 2025
Annual General Meeting 2025
Sydney, Australia
December 9, 2025 – December 12, 2025
San Antonio Breast Cancer Symposium (SABCS) 2025
San Antonio, Texas
January 12, 2026 – January 15, 2026
J.P. Morgan 44th Annual Healthcare Conference
San Francisco, CA
Please fill out the registration form below to receive updates and announcements by e-mail.
*Required
I/We authorise you to act in accordance with my/our instructions set out above.
The privacy policy was read and accepted.
